Last week, I had the privilege of representing AstraZeneca at a roundtable in London with the Prime Minister of Malaysia, Dato’ Seri Anwar Ibrahim. It was a fantastic opportunity to strengthen ties between the UK and Malaysia while highlighting AstraZeneca’s unwavering commitment to improving healthcare outcomes and advancing the life sciences industry globally.
During the discussion, I shared how AstraZeneca is leading clinical trials in Malaysia and driving innovative collaborations, such as applying UK-developed AI to enhance lung health diagnostics. These partnerships underline the incredible potential of international collaboration in addressing global healthcare challenges.
I also emphasized the importance of creating efficient regulatory and reimbursement environments, which are critical to accelerating access to ground-breaking treatments. With over 20 new medicines anticipated to launch over the next five years in Malaysia, this is more important than ever.
